## Nasdaq Regulation



**Arnold Golub** Vice President Deputy General Counsel

May 24, 2024

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on May 15, 2024, The Nasdaq Stock Market (the "Exchange") received from Inhibrx Biosciences, Inc. (the "Registrant") a copy of the Registrant's application on Form 10-12(b) for the registration of the following securities:

Common stock, par value \$0.0001 per share

We further certify that the securities described above have been approved by the Exchange for listing and registration upon official notice of issuance.

Sincerely,

all ish